GE HealthCare
GEHC
$64.13
-0.49%
GE HealthCare Technologies is a leading medical technology company that develops, manufactures, and services imaging systems (MRI, CT, ultrasound, X-ray), advanced visualization and digital solutions, patient care and monitoring equipment, and pharmaceutical diagnostics used in clinical settings worldwide. Spun off from General Electric in December 2022, the company holds leading market share in imaging and ultrasound equipment, operates across four reporting segments — Imaging (45% of revenue), Advanced Visualization Solutions (26%), Patient Care Solutions (15%), and Pharmaceutical Diagnostics (14%) — and generates roughly half of its revenue from recurring sources such as servicing, contrast agents, and digital software. The current investor narrative is dominated by a sharp reset in expectations: management lowered 2026 earnings guidance in late April 2026, citing approximately $250 million in cost inflation that long equipment sales cycles make difficult to offset quickly, triggering a violent single-day share price decline and a subsequent analyst downgrade cycle. Debates now center on whether the cost pressure is transitory or structural, how China stimulus and tariff dynamics affect order flow, and whether the company's mid-single-digit revenue growth and margin recovery story can be restored — a question made more urgent by the stock's persistent underperformance versus the broader market.…
GEHC
GE HealthCare
$64.13
Related headlines
Investment Opinion: Should I buy GEHC Today?
The synthesized recommendation is Hold, reflecting a balance between deep valuation and significant near-term headwinds. The analyst consensus is Buy with a mean of 1.74 and an average target of $82.50, implying 28.6% upside, but the recent guidance cut and margin deterioration warrant caution until there is evidence of stabilization. The core thesis is that GEHC is a high-quality franchise trading at a distressed multiple, but the catalyst for a re-rating is not yet visible.
Supporting evidence includes the forward PE of 11.85x, which is well below the medtech peer average of 20-25x, and a price-to-sales ratio of 1.82x. Revenue grew 7.41% YoY in Q1 2026, but net margin fell to 7.58% from 11.81%, and free cash flow dropped to $112 million in Q1 2026 from $917 million in Q4 2025. The dividend yield is negligible at 0.17%, and the payout ratio is only 3.07%, so income is not a factor. The implied upside to the average target is substantial, but the low target of $70.00 suggests limited downside according to analysts, though the market price is below that.
Key risks include the $250 million cost inflation, which may persist, and the technical downtrend that could break the 52-week low of $58.75. The rating would upgrade to Buy if gross margin stabilizes above 40% and free cash flow recovers above $300 million per quarter, or downgrade to Sell if revenue growth falls below 5% or if the stock breaks below $58.75. Relative to its history, the forward PE is near the low end of its range, suggesting the stock is undervalued if the recovery materializes, but fairly valued if margins remain compressed.
Sign up to view all
GEHC 12-Month Price Forecast
The risk/reward is balanced, with deep valuation offset by deteriorating fundamentals. The stock is pricing in a high probability of a cost recovery, but the recent guidance cut and margin compression suggest the path is uncertain. The low beta and recurring revenue provide some downside protection, but the technical downtrend and cash flow weakness are concerning. I would upgrade to bullish if gross margin stabilizes above 40% and free cash flow recovers, and downgrade to bearish if revenue growth falls below 5% or the stock breaks $58.75.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on GE HealthCare's 12-month outlook, with a consensus price target around $82.50 and implied upside of +28.6% versus the current price.
Average Target
$82.50
0 analysts
Implied Upside
+28.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $96
Analyst target range
Coverage is robust with 18 analysts, and the consensus recommendation is "buy" with a recommendation mean of 1.74 (where 1.0 is a strong buy and 5.0 is a strong sell), indicating a moderately bullish tilt. The average target price is $82.50, which implies +28.6% upside from the current price of $64.13 — a substantial gap that reflects analyst expectations of a recovery that the market is not yet pricing in. The consensus is therefore bullish in absolute terms, but the divergence between the buy rating and the stock's -22.57% YTD performance suggests analysts are either early or wrong; the recent downgrade by Goldman Sachs from Buy to Neutral (April 30, 2026) and UBS's upgrade from Sell to Neutral (May 21, 2026) show a mixed but net-cautious revision trend, with more firms moving to the sidelines than adding exposure. The target range spans $70.00 to $96.00, a spread of $26.00 (40.5% of the low target), which signals meaningful disagreement about the company's trajectory. The high target of $96.00 implies roughly +49.7% upside and likely assumes successful cost mitigation, margin recovery to the 15%+ operating range, and a re-rating toward the forward PE of 15–16x on restored earnings power; it may also embed China stimulus benefits and new product cycle momentum. The low target of $70.00 implies +9.2% upside and prices in a scenario where cost inflation persists, margins remain compressed, and the stock merely mean-reverts to the low end of its historical multiple without an earnings recovery. Notably, even the low target sits above the current price, meaning no analyst in the coverage universe has a target below the market — a configuration that typically signals either a genuine value disconnect or a lagging analyst community that has not fully marked down estimates. The wide spread and the clustering of recent rating actions at Neutral suggest conviction is low, and the stock's low beta (0.821) combined with a short ratio of 6.58 (days to cover) indicates that while short interest is not extreme, there is enough bearish positioning to create squeeze potential if a positive catalyst emerges.
Bulls vs Bears: GEHC Investment Factors
The bear case currently has stronger evidence due to concrete margin deterioration, cash flow weakness, and a clear technical downtrend. The bull case rests on valuation and analyst targets, which are forward-looking and depend on a cost recovery that has not yet materialized. The single most important tension is whether the $250 million cost inflation is transitory or structural; if transitory, the forward PE of 11.85x is a bargain, but if structural, earnings estimates will be revised lower and the stock could break below $58.75. The divergence between the consensus buy rating and the stock's -22.57% YTD performance highlights the market's skepticism, and until management demonstrates cost control, the risk/reward remains skewed to the downside.
Bullish
- Deep valuation discount to peers: Forward PE of 11.85x is roughly 40-45% below the 20-25x typical for large-cap medtech peers, despite GEHC's leading market share in imaging and ultrasound. The trailing PE of 17.99x sits mid-range historically, but the forward multiple prices in significant pessimism.
- Analyst targets imply substantial upside: The consensus average target of $82.50 offers 28.6% upside from $64.13, and even the lowest target of $70.00 implies 9.2% upside. With 18 analysts and a recommendation mean of 1.74 (buy), the sell-side sees recovery potential.
- Recurring revenue provides stability: Approximately half of revenue is recurring, from servicing (~33%), pharmaceutical diagnostics (~10-15%), and digital solutions (~5%). This base cushions equipment cyclicality and supports cash flow even when order flow slows.
- Low beta limits market-driven downside: Beta of 0.821 means the stock is ~18% less volatile than the market, so macro selloffs should have less impact. The recent decline is company-specific, and any resolution of cost issues could trigger a sharp re-rating.
Bearish
- Margin compression is severe: Q1 2026 gross margin fell to 38.53% from 42.12% a year earlier, and net margin dropped to 7.58% from 11.81%. Net income declined 31% YoY to $389 million despite 7.41% revenue growth, showing costs are outpacing sales.
- Cost inflation headwind is material: Management cut 2026 guidance due to $250 million in cost inflation that long equipment sales cycles make difficult to offset quickly. This triggered a violent selloff and analyst downgrades, including Goldman Sachs moving to Neutral.
- Free cash flow deterioration: Q1 2026 free cash flow was only $112 million, down sharply from $917 million in Q4 2025 and $483 million in Q3 2025. The cash balance fell from $4.515 billion to $2.288 billion due to a $2.5 billion investing outflow.
- Technical downtrend persists: The stock is down 22.57% YTD versus the S&P 500's +11.70%, a relative strength of -34.27 percentage points. It trades at just 17.4% of its 52-week range, only $5.38 above the annual low of $58.75.
GEHC Technical Analysis
GE HealthCare is in a sustained downtrend with a recovery attempt that has stalled. The stock's 1-year price change is -13.34%, and it is trading at just 17.4% of its 52-week range (52-week low of $58.75, high of $89.77), with the current price of $64.13 sitting only $5.38 above the annual low — positioning that reflects persistent distribution rather than a healthy pullback. The year-to-date decline of -22.57% versus the S&P 500's +11.70% (relative strength of -34.27 percentage points) confirms severe relative weakness, meaning the stock is not merely consolidating but actively losing ground against the market. This positioning near the lower end of the range suggests either a deep-value setup or a falling knife, and the burden of proof rests on a fundamental catalyst to reverse the trend. Recent momentum has deteriorated sharply: the 1-month change is -14.06% versus the S&P 500's -0.96%, producing a relative strength of -13.10 percentage points in just four weeks, while the 3-month change remains marginally positive at +4.12%. This divergence — a positive 3-month but deeply negative 1-month reading — indicates that the July–August rally (from roughly $61 in late July to $74.82 by August 21) has fully reversed, with the stock giving back all of those gains in September. The 6-month change of -7.93% versus the S&P 500's +17.44% (relative strength -25.37 points) reinforces that the September selloff is a resumption of the primary downtrend rather than an isolated dip. Key technical levels are well defined: support rests at the 52-week low of $58.75, roughly 8.4% below the current price of $64.13, while resistance sits at the 52-week high of $89.77, approximately 40% above. A breakdown below $58.75 would signal a new leg lower and likely trigger momentum-driven selling, whereas reclaiming the $70–$72 zone (the August consolidation area) would be the first evidence of a durable bottom. The stock's beta of 0.821 indicates it is roughly 18% less volatile than the market, which is unusual for a name in a downtrend and suggests the decline is driven by company-specific fundamentals rather than broad market beta — a distinction that matters for position sizing, as the risk here is idiosyncratic and less hedgeable through index exposure. The maximum drawdown of -32.53% over the period underscores that despite the low beta, the stock has delivered substantial peak-to-trough pain.
Beta
0.82
0.82x market volatility
Max Drawdown
-32.5%
Largest decline past year
52-Week Range
$59-$90
Price range past year
Annual Return
-13.3%
Cumulative gain past year
| Period | GEHC Return | S&P 500 |
|---|---|---|
| 1m | -14.1% | -0.5% |
| 3m | +4.1% | +2.3% |
| 6m | -7.9% | +16.6% |
| 1y | -13.3% | +14.8% |
| ytd | -22.6% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GEHC Fundamental Analysis
Revenue growth remains positive but is decelerating against a backdrop of rising costs. The most recent quarter (Q1 2026, ended March 31, 2026) reported revenue of $5.131 billion, up 7.41% year-over-year from $4.777 billion in Q1 2025, and the sequential trend shows $4.674 billion in Q4 2025, $5.143 billion in Q3 2025, and $5.006 billion in Q2 2025 — a broadly stable top line in the $4.7–$5.1 billion range with modest seasonal strength in Q1 and Q3. Segment data for the quarter shows Imaging at $2.299 billion, Pharmaceutical Diagnostics at $770 million, and Patient Care Solutions at $704 million, with Imaging remaining the dominant growth engine and the recurring revenue base (servicing, PDx, digital) providing roughly half of total sales, which cushions the cyclicality of equipment orders. However, the 7.41% YoY growth is being outpaced by the $250 million cost inflation headwind management flagged, meaning revenue growth is not translating into commensurate earnings growth — the core of the current investment debate. Profitability is deteriorating on both a sequential and year-over-year basis. Q1 2026 net income was $389 million (net margin of 7.58%) versus $564 million in Q1 2025 (net margin of 11.81%), a 31% decline in absolute profit despite higher revenue, and gross margin compressed to 38.53% from 42.12% a year earlier. The trailing twelve-month picture is similarly pressured: the Q4 2025 quarter showed a gross margin of 54.30% (flattered by year-end adjustments) but a net margin of only 3.94%, while Q3 2025 net margin was 8.67% and Q2 2025 was 9.71% — a clear downward trajectory through the year. Operating margin of 13.39% and net margin of 10.10% (per valuation data) are respectable for a medical device manufacturer but are trending toward the lower end of the company's historical band, and the gap between gross margin (39.99%) and operating margin (13.39%) highlights a heavy SG&A and R&D burden that limits operating leverage when costs rise. The balance sheet is leveraged but manageable, with debt-to-equity of 0.964 and a current ratio of 1.175, indicating adequate but not comfortable short-term liquidity. Free cash flow is the key concern: TTM free cash flow is $1.52 billion, but Q1 2026 free cash flow was only $112 million on operating cash flow of $290 million and capital expenditure of $178 million, a sharp drop from Q4 2025's $917 million FCF and Q3 2025's $483 million. The Q1 2026 cash flow statement also shows a $2.227 billion net cash outflow, driven by $2.309 billion in other investing activities and a $2.5 billion net cash outflow from investing, which reduced cash from $4.515 billion to $2.288 billion — a material liquidity drawdown that warrants monitoring. ROE of 20.08% and ROA of 5.13% remain healthy on a trailing basis, but the quarterly ROE of 3.65% (Q1 2026) shows the annualized figure is being propped up by prior periods; the company's ability to fund its dividend (payout ratio of just 3.07%) and modest buybacks ($100 million in Q1 2026) from internally generated cash is not in question, but the margin compression is eroding the cash generation that supports the valuation.
Quarterly Revenue
$5.1B
2026-03
Revenue YoY Growth
+7.4%
YoY Comparison
Gross Margin
38.5%
Latest Quarter
Free Cash Flow
$1.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GEHC Overvalued?
Because GE HealthCare is profitable — Q1 2026 net income of $389 million and trailing EPS of $0.056 (distorted by one-time items) — the PE ratio is the appropriate primary metric, though the trailing figure of 17.99x is less informative than the forward PE of 11.85x given the earnings volatility. The gap between the trailing PE of 17.99x and the forward PE of 11.85x is unusually wide, implying the market expects a substantial earnings recovery — consensus estimated EPS of $7.30 versus the trailing figure — which is a high-conviction bet that the current cost inflation is transitory. If that recovery fails to materialize, the forward multiple will prove illusory and the stock will re-rate lower; if it succeeds, the forward PE of 11.85x is genuinely cheap for a market-leading medical device franchise. On a price-to-sales basis, the stock trades at 1.82x, and EV/EBITDA is 11.34x, both of which are moderate for the sector. Relative to the medical devices industry, GE HealthCare screens as a value proposition: a forward PE of 11.85x is well below the typical 20–25x range for large-cap medtech peers, and the PEG ratio of 4.14 (while elevated due to depressed near-term growth) reflects the market's skepticism about the earnings trajectory. The premium/discount assessment is complicated by the fact that GEHC's gross margin of 39.99% and operating margin of 13.39% are below the medtech peer average (many peers operate at 55–65% gross margins), which structurally justifies a discount — but a forward PE of 11.85x versus a sector average in the low-20s represents a roughly 40–45% discount that appears to over-penalize a business with leading market share and half of revenue recurring. The discount is defensible only if the cost inflation is permanent; if it is transitory, the stock is mispriced. Historically, GE HealthCare's PE ratio has ranged from a low of 12.37x (Q4 2024) to a high of 50.01x (Q4 2025, distorted by a weak quarter), with a more typical range of 16–22x during 2023–2024. The current trailing PE of 17.99x sits in the middle of that historical band, but the forward PE of 11.85x is near the bottom of the range, suggesting the market is pricing in either a value opportunity or a fundamental deterioration that the historical multiple does not yet reflect. The price-to-book ratio of 3.61x is below the 2024 peak of 5.16x and the 2023 peak of 5.57x, consistent with a de-rating, while the price-to-free-cash-flow ratio of 18.83x (per valuation data) is elevated relative to the historical median, reflecting the compressed FCF base. The stock is not at an all-time valuation extreme, but the combination of a low forward PE and a depressed price suggests the market is applying a significant risk premium that will only compress if management demonstrates cost control and margin stabilization.
PE
18.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are elevated due to margin compression and cash flow deterioration. Q1 2026 gross margin fell to 38.53% from 42.12% a year earlier, and net margin dropped to 7.58% from 11.81%, resulting in a 31% decline in net income to $389 million despite 7.41% revenue growth. Free cash flow in Q1 2026 was only $112 million, a sharp drop from $917 million in Q4 2025, and the cash balance fell from $4.515 billion to $2.288 billion due to a $2.5 billion investing outflow. The debt-to-equity ratio of 0.964 and current ratio of 1.175 indicate adequate but not comfortable liquidity, and the $250 million cost inflation headwind may persist given long equipment sales cycles. Additionally, revenue concentration in Imaging (45% of revenue) exposes the company to segment-specific slowdowns.
Market and competitive risks include valuation compression if the earnings recovery fails to materialize. The forward PE of 11.85x is low, but the PEG ratio of 4.14 suggests the market is skeptical of growth, and the stock trades at a premium on price-to-free-cash-flow (18.83x) due to depressed FCF. The beta of 0.821 indicates lower market correlation, but the stock has underperformed the S&P 500 by 34.27 percentage points YTD, reflecting company-specific issues. Competitive threats from AI-driven diagnostic automation, such as RadNet's $270 million acquisition of Gleamer, could disrupt GEHC's imaging business. Regulatory and tariff dynamics, especially in China (11% of revenue), add uncertainty, and the recent Goldman Sachs downgrade highlights shifting sentiment.
In a worst-case scenario, if cost inflation proves structural and revenue growth decelerates, the stock could retest its 52-week low of $58.75, representing an 8.4% decline from the current price of $64.13. A breakdown below that level could trigger momentum selling and push the stock toward the analyst low target of $70.00, which is actually above the current price, suggesting limited downside according to analysts, but the market may overshoot. The maximum drawdown over the past period was -32.53%, and if earnings estimates are revised down, the forward PE could expand, leading to a further de-rating. In a severe recession or competitive disruption, the stock could fall to the $50-55 range, implying a 15-20% loss from current levels.
FAQ
The most severe risk is margin compression: Q1 2026 gross margin fell to 38.53% from 42.12%, and net margin dropped to 7.58% from 11.81%, with $250 million in cost inflation that may persist. Second, cash flow deterioration: Q1 2026 free cash flow was only $112 million, down from $917 million in Q4 2025, and the cash balance fell by $2.2 billion. Third, competitive threats from AI-driven diagnostics, such as RadNet's acquisition of Gleamer, could disrupt GEHC's imaging business. Fourth, macro and regulatory risks, including China exposure (11% of revenue) and tariff uncertainties. The stock is also in a technical downtrend, with a break below $58.75 potentially triggering further selling.
The 12-month forecast is neutral with a base case probability of 55%, targeting a range of $70.00 to $82.50. The bull case (25% probability) targets $82.50 to $96.00 if cost inflation is mitigated and margins recover. The bear case (20% probability) targets $58.75 to $70.00 if cost pressures persist and revenue growth slows. The most likely scenario is the base case, assuming gradual margin recovery and mid-single-digit revenue growth. Key assumptions include stabilization of gross margin above 38% and free cash flow improvement. The analyst average target of $82.50 aligns with the base case upper bound.
GEHC appears undervalued on a forward basis. The forward PE of 11.85x is roughly 40-45% below the 20-25x typical for large-cap medtech peers, and the price-to-sales ratio of 1.82x is moderate. However, the trailing PE of 17.99x is mid-range historically, and the PEG ratio of 4.14 suggests the market is pricing in low growth. The stock trades at a premium on price-to-free-cash-flow (18.83x) due to depressed FCF. The valuation implies the market expects the cost inflation to be structural, but if it proves transitory, the stock is significantly undervalued. Relative to its own history, the forward PE is near the low end, suggesting a value opportunity if earnings recover.
GEHC presents a mixed risk/reward. The stock trades at a forward PE of 11.85x, well below medtech peers, and the analyst average target of $82.50 implies 28.6% upside. However, the company recently cut 2026 guidance due to $250 million in cost inflation, and margins have compressed significantly, with net margin falling to 7.58% in Q1 2026 from 11.81% a year earlier. The technical trend is negative, with the stock down 22.57% YTD and trading near its 52-week low of $58.75. For value investors with a long horizon, the discount may be attractive, but near-term risks are high. It is a good buy only if you believe the cost pressures are transitory and can tolerate further downside.
GEHC is more suitable for long-term investment given its low beta (0.821), recurring revenue base, and deep valuation, but near-term volatility is high. The stock is down 22.57% YTD and has a max drawdown of -32.53%, so short-term trading is risky. The negligible dividend (0.17% yield) means income is not a factor. Earnings visibility is currently low due to cost inflation, but the company's market leadership and half of revenue from recurring sources support a multi-year holding period. A minimum holding period of 2-3 years is suggested to allow for margin recovery and potential re-rating. Short-term traders should wait for a technical bottom, such as a reclaim of $70-72.